Global Hepatitis B Vaccines Supply, Demand and Key Producers, 2026-2032
Description
The global Hepatitis B Vaccines market size is expected to reach $ 2333 million by 2032, rising at a market growth of 6.3% CAGR during the forecast period (2026-2032).
Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.In 2025, global Hepatitis B vaccine production reached approximately 391 million doses and price si about 3.72 USD/dose.The average gross profit margin of this product is 70%.
The fundamental drivers of the HepB vaccine market are the certainty of national immunization programs and long-term public-health goals tied to reducing HBV-related burden. Routine infant and pediatric vaccination provides a stable demand base in many regions, while increasingly risk-stratified adult prevention makes demand more visible across occupational exposure groups, people with chronic conditions or immunocompromise, and settings shaped by mobility and cross-border travel. In parallel, the market is evolving from single-product supply toward combination and service-enabled ecosystems, where supply stability, release capacity, cold-chain reach, and channel depth become durable competitive advantages.
As a highly regulated biologic, HepB vaccines face challenges centered on quality consistency and supply reliability. From antigen expression and purification to adjuvant compatibility and fill-finish, small process variations can escalate into batch-release and reputational risks. Public trust is also critical: safety communication, pharmacovigilance, and adverse-event management must be systematic and credible. Structurally, mature program markets may intensify price- and tender-driven commoditization, while adult and international markets depend on indication strategy, vaccination adherence, and affordability to convert potential demand into realized uptake.
Downstream demand is shifting from “coverage-driven” to “population precision and life-course management.” Pediatric pathways increasingly integrate with perinatal and maternal–child health workflows, while adult pathways emphasize high-risk identification, occupational-health linkage, and standardized post-exposure prevention routines. Another notable trend is the structural impact of combination vaccines and convenience: simpler schedules and more digital follow-up can materially improve catch-up and adult access. At the same time, mobility and global health collaboration raise expectations for stable supply, traceability systems, and multi-jurisdiction compliance readiness.
Upstream value concentrates on the biomanufacturing inputs required for recombinant antigen production and sterile drug-product processing: cell banks/strains and media systems, fermentation or cell-culture consumables, purification materials such as chromatography resins and ultrafiltration membranes, and formulation components including adjuvants, buffers, and stabilizers. In fill-finish and packaging, consistency requirements extend to vials or prefilled syringes, stoppers and seals, labeling and serialization/traceability, and cold-chain packaging materials. Overall, the grade, continuity, and change-control discipline of upstream supplies directly shape batch-to-batch consistency, release efficiency, and predictable scale delivery.
This report studies the global Hepatitis B Vaccines production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Hepatitis B Vaccines and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Hepatitis B Vaccines that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Hepatitis B Vaccines total production and demand, 2021-2032, (M Doses)
Global Hepatitis B Vaccines total production value, 2021-2032, (USD Million)
Global Hepatitis B Vaccines production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (M Doses), (based on production site)
Global Hepatitis B Vaccines consumption by region & country, CAGR, 2021-2032 & (M Doses)
U.S. VS China: Hepatitis B Vaccines domestic production, consumption, key domestic manufacturers and share
Global Hepatitis B Vaccines production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (M Doses)
Global Hepatitis B Vaccines production by Type, production, value, CAGR, 2021-2032, (USD Million) & (M Doses)
Global Hepatitis B Vaccines production by Application, production, value, CAGR, 2021-2032, (USD Million) & (M Doses)
This report profiles key players in the global Hepatitis B Vaccines market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, NCPC, Merck, Bio Kangtai, Dynavax, AIM Vaccine, KM Biologics, LG Life Sciences, Serum Institute, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Hepatitis B Vaccines market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (M Doses) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Hepatitis B Vaccines Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Hepatitis B Vaccines Market, Segmentation by Type:
Yeast Derived
CHO Derived
Global Hepatitis B Vaccines Market, Segmentation by Form Factor & Presentation:
Vial Presentation
Prefilled Syringe
Global Hepatitis B Vaccines Market, Segmentation by Adjuvant System:
Aluminum Salt Adjuvant
No Adjuvant
Other
Global Hepatitis B Vaccines Market, Segmentation by Application:
Children
Adult
Companies Profiled:
GSK
NCPC
Merck
Bio Kangtai
Dynavax
AIM Vaccine
KM Biologics
LG Life Sciences
Serum Institute
Key Questions Answered:
1. How big is the global Hepatitis B Vaccines market?
2. What is the demand of the global Hepatitis B Vaccines market?
3. What is the year over year growth of the global Hepatitis B Vaccines market?
4. What is the production and production value of the global Hepatitis B Vaccines market?
5. Who are the key producers in the global Hepatitis B Vaccines market?
6. What are the growth factors driving the market demand?
Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.In 2025, global Hepatitis B vaccine production reached approximately 391 million doses and price si about 3.72 USD/dose.The average gross profit margin of this product is 70%.
The fundamental drivers of the HepB vaccine market are the certainty of national immunization programs and long-term public-health goals tied to reducing HBV-related burden. Routine infant and pediatric vaccination provides a stable demand base in many regions, while increasingly risk-stratified adult prevention makes demand more visible across occupational exposure groups, people with chronic conditions or immunocompromise, and settings shaped by mobility and cross-border travel. In parallel, the market is evolving from single-product supply toward combination and service-enabled ecosystems, where supply stability, release capacity, cold-chain reach, and channel depth become durable competitive advantages.
As a highly regulated biologic, HepB vaccines face challenges centered on quality consistency and supply reliability. From antigen expression and purification to adjuvant compatibility and fill-finish, small process variations can escalate into batch-release and reputational risks. Public trust is also critical: safety communication, pharmacovigilance, and adverse-event management must be systematic and credible. Structurally, mature program markets may intensify price- and tender-driven commoditization, while adult and international markets depend on indication strategy, vaccination adherence, and affordability to convert potential demand into realized uptake.
Downstream demand is shifting from “coverage-driven” to “population precision and life-course management.” Pediatric pathways increasingly integrate with perinatal and maternal–child health workflows, while adult pathways emphasize high-risk identification, occupational-health linkage, and standardized post-exposure prevention routines. Another notable trend is the structural impact of combination vaccines and convenience: simpler schedules and more digital follow-up can materially improve catch-up and adult access. At the same time, mobility and global health collaboration raise expectations for stable supply, traceability systems, and multi-jurisdiction compliance readiness.
Upstream value concentrates on the biomanufacturing inputs required for recombinant antigen production and sterile drug-product processing: cell banks/strains and media systems, fermentation or cell-culture consumables, purification materials such as chromatography resins and ultrafiltration membranes, and formulation components including adjuvants, buffers, and stabilizers. In fill-finish and packaging, consistency requirements extend to vials or prefilled syringes, stoppers and seals, labeling and serialization/traceability, and cold-chain packaging materials. Overall, the grade, continuity, and change-control discipline of upstream supplies directly shape batch-to-batch consistency, release efficiency, and predictable scale delivery.
This report studies the global Hepatitis B Vaccines production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Hepatitis B Vaccines and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Hepatitis B Vaccines that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Hepatitis B Vaccines total production and demand, 2021-2032, (M Doses)
Global Hepatitis B Vaccines total production value, 2021-2032, (USD Million)
Global Hepatitis B Vaccines production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (M Doses), (based on production site)
Global Hepatitis B Vaccines consumption by region & country, CAGR, 2021-2032 & (M Doses)
U.S. VS China: Hepatitis B Vaccines domestic production, consumption, key domestic manufacturers and share
Global Hepatitis B Vaccines production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (M Doses)
Global Hepatitis B Vaccines production by Type, production, value, CAGR, 2021-2032, (USD Million) & (M Doses)
Global Hepatitis B Vaccines production by Application, production, value, CAGR, 2021-2032, (USD Million) & (M Doses)
This report profiles key players in the global Hepatitis B Vaccines market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, NCPC, Merck, Bio Kangtai, Dynavax, AIM Vaccine, KM Biologics, LG Life Sciences, Serum Institute, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Hepatitis B Vaccines market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (M Doses) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Hepatitis B Vaccines Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Hepatitis B Vaccines Market, Segmentation by Type:
Yeast Derived
CHO Derived
Global Hepatitis B Vaccines Market, Segmentation by Form Factor & Presentation:
Vial Presentation
Prefilled Syringe
Global Hepatitis B Vaccines Market, Segmentation by Adjuvant System:
Aluminum Salt Adjuvant
No Adjuvant
Other
Global Hepatitis B Vaccines Market, Segmentation by Application:
Children
Adult
Companies Profiled:
GSK
NCPC
Merck
Bio Kangtai
Dynavax
AIM Vaccine
KM Biologics
LG Life Sciences
Serum Institute
Key Questions Answered:
1. How big is the global Hepatitis B Vaccines market?
2. What is the demand of the global Hepatitis B Vaccines market?
3. What is the year over year growth of the global Hepatitis B Vaccines market?
4. What is the production and production value of the global Hepatitis B Vaccines market?
5. Who are the key producers in the global Hepatitis B Vaccines market?
6. What are the growth factors driving the market demand?
Table of Contents
110 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Manufacturers Competitive Analysis
- 4 United States VS China VS Rest of the World
- 5 Market Analysis by Type
- 6 Market Analysis by Form Factor & Presentation
- 7 Market Analysis by Adjuvant System
- 8 Market Analysis by Application
- 9 Company Profiles
- 10 Industry Chain Analysis
- 11 Research Findings and Conclusion
- 12 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
